Metabolic dysfunction-associated steatotic liver disease (MASLD) now affects 13% of all children and a striking 47% of obese children, representing a silent epidemic linked to rising childhood obesity rates. Genetic variants in genes like PNPLA3 and TM6SF2 influence disease susceptibility, while gut dysbiosis and increased intestinal permeability contribute to hepatic fat accumulation through the gut-liver axis. Mediterranean diet patterns combined with regular physical activity and weight loss demonstrate histological improvements in affected children. This finding represents a critical shift in how we understand liver health in the pediatric population. Unlike adult-onset liver disease, childhood MASLD offers a unique window for intervention before irreversible damage occurs. The high prevalence among obese children underscores the urgent need for population-level obesity prevention strategies, as this condition can progress to cirrhosis and liver failure. While emerging therapies like GLP-1 receptor agonists show promise in trials, lifestyle modification remains the primary treatment. However, significant gaps exist in understanding the natural history and optimal treatment approaches for younger patients, highlighting the need for age-specific research and clinical guidelines.